Hematology Clinical Trials | Clinical Trials GPS

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Alphonsus Medical Center-Baker City

from

Baker City, OR

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

MedStar Good Samaritan Hospital

from

Baltimore, MD

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Ochsner High Grove

from

Baton Rouge, LA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Indu and Raj Soin Medical Center

from

Beavercreek, OH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Waldo County General Hospital

from

Belfast, ME

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Sanford Joe Lueken Cancer Center

from

Bemidji, MN

MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Biddeford, ME

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Elizabeth Boardman Hospital

from

Boardman, OH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Northeast Georgia Medical Center Braselton

from

Braselton, GA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

IHA Hematology Oncology Consultants-Canton

from

Canton, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

SIH Cancer Institute

from

Carterville, IL

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

IHA Hematology Oncology Consultants-Chelsea

from

Chelsea, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

UCHealth Memorial Hospital Central

from

Colorado Springs, CO

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Dayton Physician LLC-Miami Valley Hospital North

from

Dayton, OH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

The Women's Imaging Center

from

Denver, CO

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Marshfield Medical Center-EC Cancer Center

from

Eau Claire, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Farmington Health Center

from

Farmington, UT

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Beaumont Hospital - Farmington Hills

from

Farmington Hills, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Ochsner Medical Center West Bank

from

Gretna, LA

Great Lakes Cancer Management Specialists-Van Elslander Cancer Center

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Grosse Pointe Woods, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Comprehensive Cancer Centers of Nevada-Horizon Ridge

from

Henderson, NV

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Hawaii Oncology Inc-Kuakini

from

Honolulu, HI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Oncology Center of The South Incorporated

from

Houma, LA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Capital Region Southwest Campus

from

Jefferson City, MO

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Monmouth Medical Center Southern Campus

from

Lakewood, NJ

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Vincent Hospital Cancer Center at Marinette

from

Marinette, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Marshfield Medical Center

from

Marshfield, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

UH Seidman Cancer Center at Lake Health Mentor Campus

from

Mentor, OH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Pacific Cancer Care-Monterey

from

Monterey, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Nebraska Medicine-Village Pointe

from

Omaha, NE

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Stanford Cancer Institute Palo Alto

from

Palo Alto, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Essentia Health - Park Rapids

from

Park Rapids, MN

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Newland Medical Associates-Pontiac

from

Pontiac, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Charles Health System-Redmond

from

Redmond, OR

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Delbert Day Cancer Institute at PCRMC

from

Rolla, MO

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Siteman Cancer Center at Saint Peters Hospital

from

Saint Peters, MO

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Summit Cancer Care-Candler

from

Savannah, GA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Regional West Medical Center Cancer Center

from

Scottsbluff, NE

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Geisinger Medical Oncology-Selinsgrove

from

Selinsgrove, PA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

South Jordan Health Center

from

South Jordan, UT

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Maine Medical Partners - South Portland

from

South Portland, ME

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Baptist Memorial Hospital and Cancer Center-Desoto

from

Southhaven, MS

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Rockwood North Cancer Treatment Center

from

Spokane, WA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Bhadresh Nayak MD PC-Sterling Heights

from

Sterling Heights, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Promedica Flower Hospital

from

Sylvania, OH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

SUNY Upstate Medical Center-Community Campus

from

Syracuse, NY

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Ascension Saint Joseph Hospital

from

Tawas City, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Gene Upshaw Memorial Tahoe Forest Cancer Center

from

Truckee, CA

Great Lakes Cancer Management Specialists-Macomb Professional Building

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Warren, MI

Myeloid Leukemia, Chronic, Chronic Phase Clinical Trial

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

City of Hope West Covina

from

West Covina, CA

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

Status: Enrolling, Phase II
Updated: 12/31/1969

Michigan Medicine

from

Ann Arbor, MI

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Status: Enrolling, Phase
Updated: 12/31/1969

from

Chapel Hill, NC

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Status: Enrolling, Phase
Updated: 12/31/1969

from

Charleston, SC

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Status: Enrolling, Phase
Updated: 12/31/1969

from

Gilroy, CA

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Status: Enrolling, Phase
Updated: 12/31/1969

from

Greenbrae, CA

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Status: Enrolling, Phase
Updated: 12/31/1969

from

Indianapolis, IN

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Status: Enrolling, Phase
Updated: 12/31/1969

from

New York, NY

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Status: Enrolling, Phase
Updated: 12/31/1969

from

Omaha, NE

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Status: Enrolling, Phase
Updated: 12/31/1969

from

Saint Louis, MO

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

Status: Enrolling, Phase I
Updated: 12/31/1969

from

Duarte, CA

Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

Status: Enrolling, Phase I
Updated: 12/31/1969

Guy's and St. Thomas' Hospital NHS Trust

from

London,

Relapsed/Refractory AML Clinical Trial

A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Status: Enrolling, Phase I
Updated: 12/31/1969

Steroid Refractory Acute Graft Versus Host Disease Clinical Trial

from

Seattle, WA

Hematology, Oncology, Other Clinical Trial

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Status: Enrolling, Phase III
Updated: 12/31/1969

Norton Children's Hospital

from

Louisville, KY

UVADEX® and ECP for the Treatment of Pediatric Patients With Steroid Refractory Acute Graft Versus Host Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

MD Anderson Cancer Care Center

from

Houston, TX

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma

Status: Enrolling, Phase I
Updated: 12/31/1969

from

Canton, OH

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma

Status: Enrolling, Phase I
Updated: 12/31/1969

from

Milwaukee, WI

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma

Status: Enrolling, Phase I
Updated: 12/31/1969

from

Scottsdale, AZ

Lenalidomide Maintenance in Plasma Cell Myeloma

Status: Enrolling, Phase II
Updated: 12/31/1969

Memorial Sloan Kettering Bergen

from

Montvale, NJ

Hemophilia Clinical Trial

ATHN 2: Factor Switching Study

Status: Enrolling, Phase
Updated: 12/31/1969

Yale Hemophilia Treatment Center

from

New Haven, CT

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

Status: Enrolling, Phase III
Updated: 12/31/1969

Greenville Health System (GHS) Cancer Institute

from

Greenville, SC

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

Status: Enrolling, Phase III
Updated: 12/31/1969

Northwell Health

from

Lake Success, NY

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

Status: Enrolling, Phase III
Updated: 12/31/1969

Albert Einstein Medical Center, Cancer Center

from

Philadelphia, PA

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Status: Enrolling, Phase III
Updated: 12/31/1969

Concord Repatriation General Hospital

from

Concord,

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Status: Enrolling, Phase III
Updated: 12/31/1969

Strong Health System

from

Rochester, NY

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Status: Enrolling, Phase III
Updated: 5/31/2017

from

Bedford, TX

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Status: Enrolling, Phase III
Updated: 5/31/2017

from

Buffalo, NY

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Status: Enrolling, Phase III
Updated: 5/31/2017

from

Fullerton, CA

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Status: Enrolling, Phase III
Updated: 5/31/2017

from

Goshen, IN

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Status: Enrolling, Phase III
Updated: 5/31/2017

from

La Crosse, WI

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Status: Enrolling, Phase III
Updated: 5/31/2017

from

Miami Beach, FL

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Status: Enrolling, Phase III
Updated: 5/31/2017

Merck Sharp & Dohme

from

North Ryde,

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Status: Enrolling, Phase III
Updated: 5/31/2017

from

Paramus, NJ

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Status: Enrolling, Phase III
Updated: 5/31/2017

from

Roanoke, VA

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Status: Enrolling, Phase III
Updated: 5/31/2017

from

Seattle, WA

Smilow Cancer Center at Yale New Haven Hospital, oncology Pharmacy

A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients

Status: Enrolling, Phase II
Updated: 12/31/1969

from

New Haven, CT

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Status: Enrolling, Phase I
Updated: 12/31/1969

Beth Israel Deaconess Med Ctr; Hem/Onc

from

Boston, MA